Latest News and Press Releases
Want to stay updated on the latest news?
-
SOUTH SAN FRANCISCO, Calif., Nov. 16, 2015 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq:CALA), a clinical stage biotechnology company focused on the development of novel cancer...
-
-Single Agent Solid Tumor Clinical Benefit Seen With Tumor Metabolism Inhibitor CB-839 -Continued Signs of Activity, Tolerability, and Durability -First Preclinical Data Presented For...
-
- Single Agent Solid Tumor Clinical Benefit Seen With Tumor Metabolism Inhibitor CB-839 - Continued Signs of Activity, Tolerability, and Durability SOUTH SAN FRANCISCO, Calif., Nov. 08,...
-
Potential to Combine With Anti-CTLA-4, Anti-PD-1 and Other Immuno-Oncology TherapiesIND Filing Remains on Track for 1H2016 SOUTH SAN FRANCISCO, Calif., Nov. 06, 2015 (GLOBE NEWSWIRE) -- ...
-
SOUTH SAN FRANCISCO, Calif., Nov. 05, 2015 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq:CALA), announced today that four abstracts highlighting the potential of CB-839, the Company’s...
-
SOUTH SAN FRANCISCO, Calif., Oct. 30, 2015 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq:CALA), a clinical-stage pharmaceutical company focused on discovering and developing novel small...
-
SOUTH SAN FRANCISCO, Calif., Oct. 26, 2015 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq:CALA), a clinical stage biotechnology company focused on the development of novel cancer...
-
SOUTH SAN FRANCISCO, Calif., Sept. 30, 2015 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq:CALA), a clinical-stage pharmaceutical company focused on discovering and developing novel small...
-
SOUTH SAN FRANCISCO, Calif., Sept. 23, 2015 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq:CALA), a clinical-stage pharmaceutical company focused on discovering and developing novel small...
-
SOUTH SAN FRANCISCO, Calif., Sept. 2, 2015 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq:CALA), a clinical-stage pharmaceutical company focused on discovering and developing novel small...